Modulation of alternative splicing by antisense oligonucleotides.
Sazani
P
P
Department of Pharmacology, University of North Carolina, CB #7295, Chapel Hill, North Carolina 27599-7295, USA.
Kole
R
R
D017398:Alternative Splicing; D000818:Animals; D002467:Cell Nucleus / Q000378:metabolism; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000378:metabolism; D003593:Cytoplasm / Q000378:metabolism; D004260:DNA Repair; D016189:Dystrophin / Q000378:metabolism; D005914:Globins / Q000378:metabolism*; D006801:Humans; D008956:Models, Chemical; D008957:Models, Genetic; D009369:Neoplasms / Q000378:metabolism; D016376:Oligonucleotides, Antisense / Q000378:metabolism* / Q000494:pharmacology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D016271:Proto-Oncogene Proteins c-myc / Q000378:metabolism; D012313:RNA / Q000378:metabolism; D018123:Receptors, Interleukin / Q000378:metabolism; D053649:Receptors, Interleukin-5; D051020:bcl-X Protein; D016875:tau Proteins / Q000378:metabolism
C494811:BCL2L1 protein, human; C505032:CFTR protein, human; D016189:Dystrophin; D016376:Oligonucleotides, Antisense; D019253:Proto-Oncogene Proteins c-bcl-2; D016271:Proto-Oncogene Proteins c-myc; D018123:Receptors, Interleukin; D053649:Receptors, Interleukin-5; D051020:bcl-X Protein; D016875:tau Proteins; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D012313:RNA; D005914:Globins